The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 03, 2018

Filed:

Sep. 03, 2015
Applicants:

Institut National DE LA Sante ET DE LA Recherche Medicale (Inserm), Paris, FR;

Universite Paris Descartes, Paris, FR;

Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;

Assistance Publique-hopitaux DE Paris, Paris, FR;

Universite Paris Diderot—paris 7, Paris, FR;

Imagine, Paris, FR;

Inventors:

Laurence Legeai-Mallet, Paris, FR;

Arnold Munnich, Paris, FR;

Patricia Busca, Paris, FR;

Florent Barbault, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/497 (2006.01); A61K 31/506 (2006.01); C08J 5/18 (2006.01); C08L 51/04 (2006.01); B32B 27/30 (2006.01); B29C 47/00 (2006.01); B29K 25/00 (2006.01); B29K 35/00 (2006.01); B29K 201/00 (2006.01); B29L 31/00 (2006.01); C08L 25/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); B29C 47/0004 (2013.01); B29C 47/0054 (2013.01); B32B 27/302 (2013.01); C08J 5/18 (2013.01); C08L 51/04 (2013.01); B29K 2025/06 (2013.01); B29K 2035/00 (2013.01); B29K 2201/00 (2013.01); B29L 2031/712 (2013.01); B32B 2262/06 (2013.01); B32B 2270/00 (2013.01); B32B 2439/70 (2013.01); C08J 2325/06 (2013.01); C08J 2401/00 (2013.01); C08J 2401/02 (2013.01); C08J 2425/06 (2013.01); C08J 2425/08 (2013.01); C08J 2447/00 (2013.01); C08L 25/06 (2013.01); C08L 2203/30 (2013.01); C08L 2205/02 (2013.01); C08L 2205/025 (2013.01); C08L 2205/03 (2013.01); C08L 2205/035 (2013.01); C08L 2205/16 (2013.01);
Abstract

The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.


Find Patent Forward Citations

Loading…